Phase 2RecruitingPriority 3 · Moderate priorityNCT05976997
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Plain-language summary
This trial is testing duvelisib (an oral PI3K inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Duvelisib, Chidamide (DRUG): Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;
Duvelisib, Chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details